Metrics to compare | XLO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipXLOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.6x | −15.5x | −0.2x | |
PEG Ratio | −0.03 | 0.02 | 0.00 | |
Price/Book | 0.8x | 7.1x | 2.6x | |
Price / LTM Sales | 0.9x | 11.4x | 2.8x | |
Upside (Analyst Target) | 108.8% | 77.9% | 62.1% | |
Fair Value Upside | Unlock | 8.1% | 9.5% | Unlock |
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company’s pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.